Milad Moloudizargari
Overview
Explore the profile of Milad Moloudizargari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
770
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dona A, Tandoh T, Nigam L, Singer M, Caserta E, Murtadha M, et al.
J Hematol Oncol
. 2025 Jan;
18(1):1.
PMID: 39828738
Background: Reovirus (RV) is an oncolytic virus with natural tropism for cancer cells. We previously showed that RV administration in multiple myeloma (MM) patients was safe, but disease control associated...
2.
Murtadha M, Park M, Zhu Y, Caserta E, Napolitano O, Tandoh T, et al.
Blood
. 2024 Feb;
143(16):1599-1615.
PMID: 38394668
Treatment resistance of leukemia stem cells (LSCs) and suppression of the autologous immune system represent major challenges to achieve a cure in acute myeloid leukemia (AML). Although AML blasts generally...
3.
Roy S, Moloudizargari M, Xu C
Front Med (Lausanne)
. 2023 Aug;
10:1247320.
PMID: 37564042
No abstract available.
4.
Hekmatirad S, Moloudizargari M, Fallah M, Rahimi A, Poortahmasebi V, Asghari M
Immunopharmacol Immunotoxicol
. 2023 Jul;
45(6):788-801.
PMID: 37489565
Objectives: Rapidly growing evidence suggests that immune cells play a key role in determining tumor progression. Tumor cells are surrounded by a microenvironment composed of different cell populations including immune...
5.
Gong X, Zhang Y, He X, Moloudizargari M, Yu T, Wang L, et al.
Exp Hematol Oncol
. 2023 Jun;
12(1):57.
PMID: 37391809
Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia...
6.
Moloudizargari M, Hekmatirad S, Gharaghani S, Moghadamnia A, Najafzadehvarzi H, Asghari M
J Cancer Res Clin Oncol
. 2023 Mar;
149(10):7207-7216.
PMID: 36884117
Purpose: Exosomes are membrane-derived nano-vesicles upregulated in pathological conditions like cancer. Therefore, inhibiting their release is a potential strategy for the development of more efficient combination therapies. Neutral sphingomyelinase 2...
7.
Moloudizargari M, Asghari M, Jorgensen M, Reiter R, Kabelitz D
Front Immunol
. 2022 Aug;
13:993967.
PMID: 35990697
No abstract available.
8.
Moloudizargari M, Rahmani J, Asghari M, Goel A
Epigenomics
. 2021 Dec;
14(2):101-112.
PMID: 34894715
To study the association between miR-31 expression and clinical outcomes in colorectal cancer. A systematic search was performed and 16 studies were found eligible. To calculate the combined hazard ratio...
9.
Moloudizargari M, Asghari M, Goel A
Biochem Pharmacol
. 2021 Aug;
192:114714.
PMID: 34332957
Rapidly growing interest in the study of extracellular vesicles (EVs) has led to the accumulation of evidence on their critical roles in various pathologies, as well as opportunities to design...
10.
Hekmatirad S, Moloudizargari M, Moghadamnia A, Kazemi S, Mohammadnia-Afrouzi M, Baeeri M, et al.
Front Immunol
. 2021 Jun;
12:692654.
PMID: 34149737
Aims: Acute myeloblastic leukemia (AML) is the most common type of acute leukemia in adults. Despite numerous treatment strategies including chemotherapy and radiotherapy, a large number of patients do not...